{"disease":{"id":"unknown-indication","name":"Unknown indication","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":50,"pipeline_drug_count":74,"trial_count":0},"drugs":{"marketed":[{"drug_id":"chembl-chembl2108611","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"INOTUZUMAB OZOGAMICIN","company_name":"","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":61,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody-drug conjugate that binds to CD22 on tumor cells, internalizes, and releases a cytotoxic agent causing DNA damage and cell death."},{"drug_id":"epoetin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"epoetin","company_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"Erythropoiesis-stimulating agent (ESA)","quality_score":10,"revenue":null,"mechanism":"Epogen stimulates erythropoiesis by the same mechanism as endogenous erythropoietin."},{"drug_id":"menc","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MenC","company_name":"Novartis Vaccines","drug_phase":"marketed","molecular_target":"Capsular polysaccharide of Neisseria meningitidis serogroup C","drug_class":"Conjugate vaccine","quality_score":46,"revenue":null,"mechanism":"MenC stimulates the immune system to produce antibodies against the capsular polysaccharide of Neisseria meningitidis serogroup C."},{"drug_id":"epoetin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"epoetin","company_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"Erythropoiesis-stimulating agent (ESA)","quality_score":10,"revenue":null,"mechanism":"Epogen stimulates erythropoiesis by the same mechanism as endogenous erythropoietin."},{"drug_id":"quetiapine-600mg","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapine 600mg","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"[\"serotonin 5-HT2A receptors\", \"dopamine D2 receptors\"]","drug_class":"atypical antipsychotic","quality_score":55,"revenue":null,"mechanism":"Quetiapine is an atypical antipsychotic that acts as a serotonin and dopamine receptor antagonist."},{"drug_id":"quetiapine-600mg","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapine 600mg","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"[\"serotonin 5-HT2A receptors\", \"dopamine D2 receptors\"]","drug_class":"atypical antipsychotic","quality_score":55,"revenue":null,"mechanism":"Quetiapine is an atypical antipsychotic that acts as a serotonin and dopamine receptor antagonist."},{"drug_id":"loncastuximab-tesirine","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LONCASTUXIMAB TESIRINE","company_name":"","drug_phase":"marketed","molecular_target":"CD19","drug_class":"Antibody-Drug Conjugate (ADC)","quality_score":50,"revenue":null,"mechanism":"Loncastuximab tesirine is an ADC that targets CD19 on B-lineage cells, internalizes, and releases a cytotoxic agent to induce cell death."},{"drug_id":"cysteamine-hydrochloride","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CYSTEAMINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Cystine","drug_class":"Cystine-depleting agents","quality_score":44,"revenue":null,"mechanism":"Cysteamine depletes cystine by converting it to cysteine and cysteine-cysteamine mixed disulfides, reducing corneal cystine crystal accumulation."},{"drug_id":"sinecatechins","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SINECATECHINS","company_name":"","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Polyphenols","quality_score":46,"revenue":null,"mechanism":"The exact mechanism of action of sinecatechins in the treatment of genital and perianal warts is unknown, but it has demonstrated anti-oxidative activity in vitro."},{"drug_id":"therapeutic-entecavir","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Therapeutic entecavir","company_name":"Taipei Veterans General Hospital, Taiwan","drug_phase":"marketed","molecular_target":"HBV DNA polymerase","drug_class":"Nucleoside analog reverse transcriptase inhibitor (NRTI)","quality_score":46,"revenue":null,"mechanism":"Entecavir is a guanosine nucleoside analog that selectively inhibits the replication of hepatitis B virus (HBV) DNA polymerase."},{"drug_id":"highly-active-antiretroviral-therapy-haart","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"highly active antiretroviral therapy (HAART)","company_name":"National Institute of Allergy and Infectious Diseases (NIAID)","drug_phase":"marketed","molecular_target":"HIV enzymes and processes","drug_class":"Antiretroviral","quality_score":42,"revenue":null,"mechanism":"HAART combines multiple antiretroviral drugs to inhibit different stages of the HIV life cycle, thereby reducing viral replication and improving immune function."},{"drug_id":"systane-balance","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Systane Balance","company_name":"Southern California College of Optometry at Marshall B. Ketchum University","drug_phase":"marketed","molecular_target":"Tear film stability","drug_class":"Lubricant eye drops","quality_score":39,"revenue":null,"mechanism":"Systane Balance is a lubricant eye drop that helps to relieve dryness and discomfort by replenishing the tear film."},{"drug_id":"prontogest-400-mg-vaginal-pessaries","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prontogest 400 mg vaginal pessaries","company_name":"Ain Shams Maternity Hospital","drug_phase":"marketed","molecular_target":"Uterine smooth muscle and cervical tissue","drug_class":"Progesterone","quality_score":42,"revenue":null,"mechanism":"Prontogest 400 mg vaginal pessaries work by delivering progesterone to the vaginal mucosa, which helps maintain uterine quiescence and prevent preterm labor."},{"drug_id":"almotriptan-malate","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ALMOTRIPTAN MALATE","company_name":"","drug_phase":"marketed","molecular_target":"5-HT1B/1D receptors","drug_class":"Triptan","quality_score":52,"revenue":null,"mechanism":"Almotriptan malate is a selective 5-HT1B/1D receptor agonist that binds with high affinity to these receptors, leading to vasoconstriction and inhibition of neurogenic inflammation."},{"drug_id":"almotriptan-malate","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ALMOTRIPTAN MALATE","company_name":"","drug_phase":"marketed","molecular_target":"5-HT1B/1D receptors","drug_class":"Triptan","quality_score":52,"revenue":null,"mechanism":"Almotriptan malate is a selective 5-HT1B/1D receptor agonist that binds with high affinity to these receptors, leading to vasoconstriction and inhibition of neurogenic inflammation."},{"drug_id":"suprep-bowel-prep-kit","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SUPREP Bowel Prep Kit","company_name":"Braintree Laboratories","drug_phase":"marketed","molecular_target":"Intestinal lumen","drug_class":"Osmotic laxative","quality_score":null,"revenue":null,"mechanism":"SUPREP works by drawing water into the intestines to flush out the contents, preparing the bowel for colonoscopy."},{"drug_id":"telotristat-etiprate","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TELOTRISTAT ETIPRATE","company_name":"","drug_phase":"marketed","molecular_target":"Tryptophan Hydroxylase-1 (TPH1)","drug_class":"Serotonin Synthesis Inhibitor","quality_score":null,"revenue":null,"mechanism":"Telotristat etiprate inhibits tryptophan hydroxylase, the rate-limiting enzyme in serotonin synthesis, thereby reducing serotonin levels in the body."},{"drug_id":"detralex","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Detralex","company_name":"Servier Russia","drug_phase":"marketed","molecular_target":"Venous tone and microcirculation","drug_class":"Venoactive drug","quality_score":null,"revenue":null,"mechanism":"Detralex works by enhancing venous tone and microcirculation through the action of diosmin and hesperidin."},{"drug_id":"detralex","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Detralex","company_name":"Servier Russia","drug_phase":"marketed","molecular_target":"Venous tone and microcirculation","drug_class":"Venoactive drug","quality_score":null,"revenue":null,"mechanism":"Detralex works by enhancing venous tone and microcirculation through the action of diosmin and hesperidin."},{"drug_id":"flupentixole","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flupentixole","company_name":"Technical University of Munich","drug_phase":"marketed","molecular_target":"Dopamine D2 receptors","drug_class":"Antipsychotic","quality_score":null,"revenue":null,"mechanism":"Flupentixole is a dopamine D2 receptor antagonist that reduces psychotic symptoms by blocking dopamine receptors in the brain."},{"drug_id":"flupentixole","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flupentixole","company_name":"Technical University of Munich","drug_phase":"marketed","molecular_target":"Dopamine D2 receptors","drug_class":"Antipsychotic","quality_score":null,"revenue":null,"mechanism":"Flupentixole is a dopamine D2 receptor antagonist that reduces psychotic symptoms by blocking dopamine receptors in the brain."},{"drug_id":"salmeterol-50-mcg-via-diskus","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Salmeterol 50 mcg via DISKUS","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"Beta2-adrenergic receptors","drug_class":"Long-acting beta2-adrenergic agonist (LABA)","quality_score":null,"revenue":null,"mechanism":"Salmeterol is a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle to improve airflow."},{"drug_id":"hydroxy-urea","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxy Urea","company_name":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","drug_phase":"marketed","molecular_target":"Ribonucleotide reductase","drug_class":"Antimetabolite","quality_score":null,"revenue":null,"mechanism":"Hydroxyurea inhibits ribonucleotide reductase, an enzyme essential for DNA synthesis, leading to cell cycle arrest and apoptosis in rapidly dividing cells."},{"drug_id":"hydroxy-urea","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxy Urea","company_name":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","drug_phase":"marketed","molecular_target":"Ribonucleotide reductase","drug_class":"Antimetabolite","quality_score":null,"revenue":null,"mechanism":"Hydroxyurea inhibits ribonucleotide reductase, an enzyme essential for DNA synthesis, leading to cell cycle arrest and apoptosis in rapidly dividing cells."},{"drug_id":"salmeterol-50-mcg-via-diskus","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Salmeterol 50 mcg via DISKUS","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"Beta2-adrenergic receptors","drug_class":"Long-acting beta2-adrenergic agonist (LABA)","quality_score":null,"revenue":null,"mechanism":"Salmeterol is a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle to improve airflow."},{"drug_id":"oxybutynin-immediate-release","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"oxybutynin immediate release","company_name":"Astellas Pharma Inc","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptors (M2 and M3)","drug_class":"Anticholinergic","quality_score":null,"revenue":null,"mechanism":"Oxybutynin is an anticholinergic that blocks muscarinic receptors in the bladder, leading to relaxation of the detrusor muscle and increased bladder capacity."},{"drug_id":"stopping-dupilumab","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Stopping dupilumab","company_name":"University Hospital, Toulouse","drug_phase":"marketed","molecular_target":"Interleukin-4 receptor alpha subunit (IL-4Rα)","drug_class":"Monoclonal antibody","quality_score":0,"revenue":null,"mechanism":"Dupilumab is a human monoclonal antibody that binds to the interleukin-4 receptor alpha subunit, blocking the signaling of IL-4 and IL-13, which are key cytokines in type 2 inflammation."},{"drug_id":"stopping-dupilumab","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Stopping dupilumab","company_name":"University Hospital, Toulouse","drug_phase":"marketed","molecular_target":"Interleukin-4 receptor alpha subunit (IL-4Rα)","drug_class":"Monoclonal antibody","quality_score":0,"revenue":null,"mechanism":"Dupilumab is a human monoclonal antibody that binds to the interleukin-4 receptor alpha subunit, blocking the signaling of IL-4 and IL-13, which are key cytokines in type 2 inflammation."},{"drug_id":"stopping-dupilumab","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Stopping dupilumab","company_name":"University Hospital, Toulouse","drug_phase":"marketed","molecular_target":"Interleukin-4 receptor alpha subunit (IL-4Rα)","drug_class":"Monoclonal antibody","quality_score":0,"revenue":null,"mechanism":"Dupilumab is a human monoclonal antibody that binds to the interleukin-4 receptor alpha subunit, blocking the signaling of IL-4 and IL-13, which are key cytokines in type 2 inflammation."},{"drug_id":"dexketoprofen-trometamol-pethidine-hydrochloride","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"dexketoprofen trometamol + pethidine hydrochloride","company_name":"Kavaklıdere Umut Hospital","drug_phase":"marketed","molecular_target":"[\"cyclooxygenase (COX) enzymes\", \"mu-opioid receptors\"]","drug_class":"[\"NSAID\", \"opioid analgesic\"]","quality_score":null,"revenue":null,"mechanism":"Dexketoprofen trometamol and pethidine hydrochloride work together to provide potent analgesia by reducing inflammation and acting on opioid receptors in the central nervous system."},{"drug_id":"5-albumin-infusion-3-hours","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"5% Albumin infusion 3 hours","company_name":"Region Skane","drug_phase":"marketed","molecular_target":"Intravascular volume and oncotic pressure","drug_class":"Plasma expanders","quality_score":null,"revenue":null,"mechanism":"5% Albumin infusion works by increasing intravascular volume and maintaining oncotic pressure, thereby improving blood flow and tissue perfusion."},{"drug_id":"5-albumin-infusion-3-hours","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"5% Albumin infusion 3 hours","company_name":"Region Skane","drug_phase":"marketed","molecular_target":"Intravascular volume and oncotic pressure","drug_class":"Plasma expanders","quality_score":null,"revenue":null,"mechanism":"5% Albumin infusion works by increasing intravascular volume and maintaining oncotic pressure, thereby improving blood flow and tissue perfusion."},{"drug_id":"5-albumin-infusion-3-hours","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"5% Albumin infusion 3 hours","company_name":"Region Skane","drug_phase":"marketed","molecular_target":"Intravascular volume and oncotic pressure","drug_class":"Plasma expanders","quality_score":null,"revenue":null,"mechanism":"5% Albumin infusion works by increasing intravascular volume and maintaining oncotic pressure, thereby improving blood flow and tissue perfusion."},{"drug_id":"levofloxacin-ophthalmic","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Levofloxacin Ophthalmic","company_name":"National University of Malaysia","drug_phase":"marketed","molecular_target":"DNA gyrase","drug_class":"Fluoroquinolone","quality_score":null,"revenue":null,"mechanism":"Levofloxacin ophthalmic is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase, leading to bacterial cell death."},{"drug_id":"rituximab-pvvr","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rituximab-pvvr","company_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","drug_phase":"marketed","molecular_target":"CD20 antigen","drug_class":"Monoclonal antibody","quality_score":0,"revenue":null,"mechanism":"Rituximab-pvvr is a monoclonal antibody that targets the CD20 antigen on B-lymphocytes, leading to B-cell lysis through mechanisms such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC)."},{"drug_id":"rituximab-pvvr","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rituximab-pvvr","company_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","drug_phase":"marketed","molecular_target":"CD20 antigen","drug_class":"Monoclonal antibody","quality_score":0,"revenue":null,"mechanism":"Rituximab-pvvr is a monoclonal antibody that targets the CD20 antigen on B-lymphocytes, leading to B-cell lysis through mechanisms such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC)."},{"drug_id":"rituximab-pvvr","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rituximab-pvvr","company_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","drug_phase":"marketed","molecular_target":"CD20 antigen","drug_class":"Monoclonal antibody","quality_score":0,"revenue":null,"mechanism":"Rituximab-pvvr is a monoclonal antibody that targets the CD20 antigen on B-lymphocytes, leading to B-cell lysis through mechanisms such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC)."},{"drug_id":"chlortetracycline-hydrochloride","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CHLORTETRACYCLINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"30S ribosomal subunit","drug_class":"Tetracycline","quality_score":0,"revenue":null,"mechanism":"Chlortetracycline hydrochloride inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the ribosome."},{"drug_id":"menveo-menactra","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Menveo®/Menactra®","company_name":"Massachusetts General Hospital","drug_phase":"marketed","molecular_target":"Neisseria meningitidis serogroups A, C, W, and Y","drug_class":"Conjugate vaccine","quality_score":0,"revenue":null,"mechanism":"Menveo® and Menactra® are conjugate vaccines that stimulate the immune system to produce antibodies against Neisseria meningitidis serogroups A, C, W, and Y."},{"drug_id":"riamet-artemether-lumefantrin-combination","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RIAMET (artemether + LUMEFANTRIN combination)","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"marketed","molecular_target":"Plasmodium falciparum","drug_class":"Antimalarial","quality_score":0,"revenue":null,"mechanism":"Riamet combines artemether, a fast-acting antimalarial, with lumefantrine, a longer-acting partner, to provide a synergistic effect against Plasmodium falciparum."},{"drug_id":"danicopan","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DANICOPAN","company_name":"","drug_phase":"marketed","molecular_target":"Complement Factor D","drug_class":"Complement Factor D Inhibitor","quality_score":null,"revenue":null,"mechanism":"Danicopan is a selective inhibitor of complement Factor D, preventing the cleavage of Factor B and the formation of the C3 convertase in the alternative complement pathway."},{"drug_id":"omeprazole-20mg-twice-daily","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"omeprazole, 20mg twice daily","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"H+/K+ ATPase enzyme","drug_class":"Proton Pump Inhibitor (PPI)","quality_score":54,"revenue":null,"mechanism":"Omeprazole reduces stomach acid production by irreversibly inhibiting the H+/K+ ATPase enzyme in gastric parietal cells."},{"drug_id":"omeprazole-20mg-twice-daily","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"omeprazole, 20mg twice daily","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"H+/K+ ATPase enzyme","drug_class":"Proton Pump Inhibitor (PPI)","quality_score":54,"revenue":null,"mechanism":"Omeprazole reduces stomach acid production by irreversibly inhibiting the H+/K+ ATPase enzyme in gastric parietal cells."},{"drug_id":"0-33-ropivacaine-250ml","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"0.33% ropivacaine 250ml","company_name":"Guangzhou General Hospital of Guangzhou Military Command","drug_phase":"marketed","molecular_target":"Voltage-gated sodium channels","drug_class":"Local anesthetic","quality_score":51,"revenue":null,"mechanism":"Ropivacaine is a local anesthetic that blocks sodium channels, preventing the propagation of nerve impulses."},{"drug_id":"0-33-ropivacaine-250ml","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"0.33% ropivacaine 250ml","company_name":"Guangzhou General Hospital of Guangzhou Military Command","drug_phase":"marketed","molecular_target":"Voltage-gated sodium channels","drug_class":"Local anesthetic","quality_score":51,"revenue":null,"mechanism":"Ropivacaine is a local anesthetic that blocks sodium channels, preventing the propagation of nerve impulses."},{"drug_id":"nicardipine-hydrochloride","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NICARDIPINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Calcium ion channels","drug_class":"Calcium channel blocker","quality_score":53,"revenue":null,"mechanism":"Nicardipine blocks calcium ion influx into vascular smooth muscle, causing relaxation with minimal effect on cardiac muscle."},{"drug_id":"nicardipine-hydrochloride","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NICARDIPINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Calcium ion channels","drug_class":"Calcium channel blocker","quality_score":53,"revenue":null,"mechanism":"Nicardipine blocks calcium ion influx into vascular smooth muscle, causing relaxation with minimal effect on cardiac muscle."},{"drug_id":"experimental-active-i-reconstruction-therapy","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Experimental: Active \"I-Reconstruction\" Therapy","company_name":"International Association Psychosomatics And Health Therapy","drug_phase":"marketed","molecular_target":"DNA gyrase and topoisomerase IV","drug_class":"Fluoroquinolone","quality_score":51,"revenue":null,"mechanism":"Ofloxacin ophthalmic solution is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, leading to bacterial cell death."},{"drug_id":"omeprazole-20mg-twice-daily","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"omeprazole, 20mg twice daily","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"H+/K+ ATPase enzyme","drug_class":"Proton Pump Inhibitor (PPI)","quality_score":54,"revenue":null,"mechanism":"Omeprazole reduces stomach acid production by irreversibly inhibiting the H+/K+ ATPase enzyme in gastric parietal cells."},{"drug_id":"epoetin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"epoetin","company_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"Erythropoiesis-stimulating agent (ESA)","quality_score":10,"revenue":null,"mechanism":"Epogen stimulates erythropoiesis by the same mechanism as endogenous erythropoietin."},{"drug_id":"tegoprazan-50-mg","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tegoprazan 50 mg","company_name":"First People's Hospital of Hangzhou","drug_phase":"marketed","molecular_target":"H+/K+-ATPase","drug_class":"Potassium-Competitive Acid Blocker (P-CAB)","quality_score":42,"revenue":null,"mechanism":"Tegoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits the H+/K+-ATPase enzyme, reducing gastric acid secretion."},{"drug_id":"tegoprazan-50-mg","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tegoprazan 50 mg","company_name":"First People's Hospital of Hangzhou","drug_phase":"marketed","molecular_target":"H+/K+-ATPase","drug_class":"Potassium-Competitive Acid Blocker (P-CAB)","quality_score":42,"revenue":null,"mechanism":"Tegoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits the H+/K+-ATPase enzyme, reducing gastric acid secretion."},{"drug_id":"flumist-quadrivalent-2017-2018","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FluMist Quadrivalent (2017-2018)","company_name":"MedImmune LLC","drug_phase":"marketed","molecular_target":"Influenza virus","drug_class":"Live attenuated influenza vaccine (LAIV)","quality_score":49,"revenue":null,"mechanism":"FluMist Quadrivalent is a live attenuated influenza vaccine that stimulates an immune response in the nasal passages to prevent influenza infection."},{"drug_id":"lidocaine-patch-local-application","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lidocaine patch local application","company_name":"Taipei Medical University Hospital","drug_phase":"marketed","molecular_target":"Sodium channels","drug_class":"Local anesthetic","quality_score":42,"revenue":null,"mechanism":"Lidocaine patch works by locally blocking sodium channels in nerve cells, which reduces the transmission of pain signals."},{"drug_id":"lamiduvine-epivir","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lamiduvine (Epivir)","company_name":"Catholic University of the Sacred Heart","drug_phase":"marketed","molecular_target":"HIV reverse transcriptase","drug_class":"Nucleoside Reverse Transcriptase Inhibitor (NRTI)","quality_score":51,"revenue":null,"mechanism":"Lamiduvine inhibits the HIV reverse transcriptase enzyme, preventing viral RNA from being converted into DNA, thus halting viral replication."},{"drug_id":"ceftriaxone-v-penicillin-and-gentamicin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxone v penicillin and gentamicin","company_name":"Kamuzu University of Health Sciences","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"Third-generation cephalosporin","quality_score":58,"revenue":null,"mechanism":"Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs)."},{"drug_id":"ceftriaxone-v-penicillin-and-gentamicin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxone v penicillin and gentamicin","company_name":"Kamuzu University of Health Sciences","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"Third-generation cephalosporin","quality_score":58,"revenue":null,"mechanism":"Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs)."},{"drug_id":"ceftriaxone-v-penicillin-and-gentamicin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxone v penicillin and gentamicin","company_name":"Kamuzu University of Health Sciences","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"Third-generation cephalosporin","quality_score":58,"revenue":null,"mechanism":"Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs)."},{"drug_id":"ceftriaxone-v-penicillin-and-gentamicin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxone v penicillin and gentamicin","company_name":"Kamuzu University of Health Sciences","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"Third-generation cephalosporin","quality_score":58,"revenue":null,"mechanism":"Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs)."},{"drug_id":"ceftriaxone-v-penicillin-and-gentamicin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxone v penicillin and gentamicin","company_name":"Kamuzu University of Health Sciences","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"Third-generation cephalosporin","quality_score":58,"revenue":null,"mechanism":"Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs)."},{"drug_id":"ceftriaxone-v-penicillin-and-gentamicin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxone v penicillin and gentamicin","company_name":"Kamuzu University of Health Sciences","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"Third-generation cephalosporin","quality_score":58,"revenue":null,"mechanism":"Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs)."},{"drug_id":"captopril-test-dose-and-trandolapril","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Captopril Test Dose and Trandolapril","company_name":"Rigshospitalet, Denmark","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme (ACE)","drug_class":"Angiotensin-converting enzyme (ACE) inhibitors","quality_score":55,"revenue":null,"mechanism":"Captopril and Trandolapril inhibit the angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and leading to vasodilation and decreased blood pressure."},{"drug_id":"captopril-test-dose-and-trandolapril","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Captopril Test Dose and Trandolapril","company_name":"Rigshospitalet, Denmark","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme (ACE)","drug_class":"Angiotensin-converting enzyme (ACE) inhibitors","quality_score":55,"revenue":null,"mechanism":"Captopril and Trandolapril inhibit the angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and leading to vasodilation and decreased blood pressure."},{"drug_id":"bidil-xr","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BiDil XR","company_name":"Arbor Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Vasculature and cardiac function","drug_class":"Vasodilators","quality_score":51,"revenue":null,"mechanism":"BiDil XR combines isosorbide dinitrate and hydralazine to enhance vasodilation and reduce cardiac workload, specifically benefiting patients with heart failure."},{"drug_id":"drug-treatment-with-cymbalta","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Drug treatment with Cymbalta","company_name":"Jefferson Clinic, P.C.","drug_phase":"marketed","molecular_target":"Serotonin and norepinephrine transporters","drug_class":"Serotonin-norepinephrine reuptake inhibitor (SNRI)","quality_score":58,"revenue":null,"mechanism":"Cymbalta is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain."},{"drug_id":"drug-treatment-with-cymbalta","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Drug treatment with Cymbalta","company_name":"Jefferson Clinic, P.C.","drug_phase":"marketed","molecular_target":"Serotonin and norepinephrine transporters","drug_class":"Serotonin-norepinephrine reuptake inhibitor (SNRI)","quality_score":58,"revenue":null,"mechanism":"Cymbalta is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain."},{"drug_id":"drug-treatment-with-cymbalta","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Drug treatment with Cymbalta","company_name":"Jefferson Clinic, P.C.","drug_phase":"marketed","molecular_target":"Serotonin and norepinephrine transporters","drug_class":"Serotonin-norepinephrine reuptake inhibitor (SNRI)","quality_score":58,"revenue":null,"mechanism":"Cymbalta is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain."},{"drug_id":"drug-treatment-with-cymbalta","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Drug treatment with Cymbalta","company_name":"Jefferson Clinic, P.C.","drug_phase":"marketed","molecular_target":"Serotonin and norepinephrine transporters","drug_class":"Serotonin-norepinephrine reuptake inhibitor (SNRI)","quality_score":58,"revenue":null,"mechanism":"Cymbalta is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain."},{"drug_id":"drug-treatment-with-cymbalta","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Drug treatment with Cymbalta","company_name":"Jefferson Clinic, P.C.","drug_phase":"marketed","molecular_target":"Serotonin and norepinephrine transporters","drug_class":"Serotonin-norepinephrine reuptake inhibitor (SNRI)","quality_score":58,"revenue":null,"mechanism":"Cymbalta is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases the levels of serotonin and norepinephrine in the brain."},{"drug_id":"attenuated-hepatitis-a-vaccine-h2-strain","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Attenuated Hepatitis A Vaccine, H2 Strain","company_name":"Jiangsu Province Centers for Disease Control and Prevention","drug_phase":"marketed","molecular_target":"Hepatitis A virus","drug_class":"Live attenuated vaccine","quality_score":46,"revenue":null,"mechanism":"The Attenuated Hepatitis A Vaccine, H2 Strain, works by introducing a live, weakened form of the hepatitis A virus to stimulate an immune response."},{"drug_id":"fluvastatin-tacrolimus-mycophenolat-mofetil","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluvastatin, Tacrolimus, Mycophenolat Mofetil","company_name":"University Hospital Schleswig-Holstein","drug_phase":"marketed","molecular_target":"[\"HMG-CoA reductase\", \"T-cell activation\", \"IMP dehydrogenase\"]","drug_class":"[\"Statins\", \"Immunosuppressants\", \"Immunosuppressants\"]","quality_score":10,"revenue":null,"mechanism":"Fluvastatin, Tacrolimus, and Mycophenolate Mofetil work through different mechanisms to manage hypercholesterolemia and prevent organ rejection in transplant patients."},{"drug_id":"fluvastatin-tacrolimus-mycophenolat-mofetil","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluvastatin, Tacrolimus, Mycophenolat Mofetil","company_name":"University Hospital Schleswig-Holstein","drug_phase":"marketed","molecular_target":"[\"HMG-CoA reductase\", \"T-cell activation\", \"IMP dehydrogenase\"]","drug_class":"[\"Statins\", \"Immunosuppressants\", \"Immunosuppressants\"]","quality_score":10,"revenue":null,"mechanism":"Fluvastatin, Tacrolimus, and Mycophenolate Mofetil work through different mechanisms to manage hypercholesterolemia and prevent organ rejection in transplant patients."},{"drug_id":"fluvastatin-tacrolimus-mycophenolat-mofetil","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluvastatin, Tacrolimus, Mycophenolat Mofetil","company_name":"University Hospital Schleswig-Holstein","drug_phase":"marketed","molecular_target":"[\"HMG-CoA reductase\", \"T-cell activation\", \"IMP dehydrogenase\"]","drug_class":"[\"Statins\", \"Immunosuppressants\", \"Immunosuppressants\"]","quality_score":10,"revenue":null,"mechanism":"Fluvastatin, Tacrolimus, and Mycophenolate Mofetil work through different mechanisms to manage hypercholesterolemia and prevent organ rejection in transplant patients."},{"drug_id":"montelukast-high-feno-group","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Montelukast (High FeNO group)","company_name":"Hull University Teaching Hospitals NHS Trust","drug_phase":"marketed","molecular_target":"CysLT1 receptor","drug_class":"Leukotriene receptor antagonist","quality_score":55,"revenue":null,"mechanism":"Montelukast is a selective leukotriene receptor antagonist that blocks the action of cysteinyl leukotrienes on the CysLT1 receptor, reducing inflammation and bronchoconstriction."},{"drug_id":"montelukast-high-feno-group","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Montelukast (High FeNO group)","company_name":"Hull University Teaching Hospitals NHS Trust","drug_phase":"marketed","molecular_target":"CysLT1 receptor","drug_class":"Leukotriene receptor antagonist","quality_score":55,"revenue":null,"mechanism":"Montelukast is a selective leukotriene receptor antagonist that blocks the action of cysteinyl leukotrienes on the CysLT1 receptor, reducing inflammation and bronchoconstriction."},{"drug_id":"actos-pioglitazone","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Actos (Pioglitazone)","company_name":"Taipei Veterans General Hospital, Taiwan","drug_phase":"marketed","molecular_target":"PPAR-γ","drug_class":"Thiazolidinediones","quality_score":52,"revenue":null,"mechanism":"Actos (pioglitazone) is a thiazolidinedione that enhances insulin sensitivity in peripheral tissues, particularly in adipose tissue, skeletal muscle, and liver."},{"drug_id":"flunarizine-and-or-pregabalin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"flunarizine and/or pregabalin","company_name":"Taipei Veterans General Hospital, Taiwan","drug_phase":"marketed","molecular_target":"[\"L-type calcium channels\", \"alpha2-delta subunit of voltage-gated calcium channels\"]","drug_class":"[\"Calcium Channel Blocker\", \"Anticonvulsant\"]","quality_score":51,"revenue":null,"mechanism":"Flunarizine blocks voltage-dependent calcium channels, while pregabalin binds to the alpha2-delta subunit of voltage-gated calcium channels, reducing the release of neurotransmitters."},{"drug_id":"flunarizine-and-or-pregabalin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"flunarizine and/or pregabalin","company_name":"Taipei Veterans General Hospital, Taiwan","drug_phase":"marketed","molecular_target":"[\"L-type calcium channels\", \"alpha2-delta subunit of voltage-gated calcium channels\"]","drug_class":"[\"Calcium Channel Blocker\", \"Anticonvulsant\"]","quality_score":51,"revenue":null,"mechanism":"Flunarizine blocks voltage-dependent calcium channels, while pregabalin binds to the alpha2-delta subunit of voltage-gated calcium channels, reducing the release of neurotransmitters."},{"drug_id":"fluticasone-propionate-hydrofluoroalkane-hfa","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"fluticasone propionate hydrofluoroalkane (HFA)","company_name":"Organon and Co","drug_phase":"marketed","molecular_target":"Glucocorticoid receptors","drug_class":"Inhaled corticosteroid","quality_score":10,"revenue":null,"mechanism":"Fluticasone propionate HFA is a potent inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors."},{"drug_id":"fluticasone-propionate-hydrofluoroalkane-hfa","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"fluticasone propionate hydrofluoroalkane (HFA)","company_name":"Organon and Co","drug_phase":"marketed","molecular_target":"Glucocorticoid receptors","drug_class":"Inhaled corticosteroid","quality_score":10,"revenue":null,"mechanism":"Fluticasone propionate HFA is a potent inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors."},{"drug_id":"tetanus-toxoid-reduced-diphtheria-toxoid-acellular-pertussis","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis","company_name":"Sanofi Pasteur, a Sanofi Company","drug_phase":"marketed","molecular_target":"The vaccine targets the immune system to produce antibodies against tetanus, diphtheria, and pertussis toxins.","drug_class":"Vaccine","quality_score":49,"revenue":null,"mechanism":"The Tdap vaccine works by introducing inactivated toxins from the bacteria that cause tetanus, diphtheria, and pertussis, stimulating the immune system to produce antibodies against these pathogens."},{"drug_id":"bufomix-easyhaler-160-4-5-g-inhalation-dmdpi","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI","company_name":"Orion Corporation, Orion Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptors and β2-adrenergic receptors","drug_class":"Combination of inhaled corticosteroid (ICS) and long-acting beta2-adrenergic agonist (LABA)","quality_score":49,"revenue":null,"mechanism":"Bufomix® Easyhaler® combines an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) to reduce inflammation and bronchodilation in the airways."},{"drug_id":"bufomix-easyhaler-160-4-5-g-inhalation-dmdpi","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI","company_name":"Orion Corporation, Orion Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptors and β2-adrenergic receptors","drug_class":"Combination of inhaled corticosteroid (ICS) and long-acting beta2-adrenergic agonist (LABA)","quality_score":49,"revenue":null,"mechanism":"Bufomix® Easyhaler® combines an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) to reduce inflammation and bronchodilation in the airways."},{"drug_id":"semaglutide-or-tirzepatide","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"semaglutide or tirzepatide","company_name":"Mayo Clinic","drug_phase":"marketed","molecular_target":"GLP-1 receptor","drug_class":"GLP-1 receptor agonist","quality_score":52,"revenue":null,"mechanism":"Semaglutide and tirzepatide are GLP-1 receptor agonists that enhance glucose-dependent insulin secretion and reduce glucagon secretion, leading to improved glycemic control and weight loss."},{"drug_id":"semaglutide-or-tirzepatide","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"semaglutide or tirzepatide","company_name":"Mayo Clinic","drug_phase":"marketed","molecular_target":"GLP-1 receptor","drug_class":"GLP-1 receptor agonist","quality_score":52,"revenue":null,"mechanism":"Semaglutide and tirzepatide are GLP-1 receptor agonists that enhance glucose-dependent insulin secretion and reduce glucagon secretion, leading to improved glycemic control and weight loss."},{"drug_id":"onasemnogene-abeparvovec-brve","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Onasemnogene Abeparvovec-brve","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"SMN1 gene","drug_class":"Gene Therapy","quality_score":10,"revenue":null,"mechanism":"ITVISMA delivers a functional SMN1 gene using an AAV9 vector to promote SMN protein expression in motor neurons."},{"drug_id":"epoetin","indication_name":"Unknown indication","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"epoetin","company_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","drug_phase":"marketed","molecular_target":"Erythropoietin receptor","drug_class":"Erythropoiesis-stimulating agent (ESA)","quality_score":10,"revenue":null,"mechanism":"Epogen stimulates erythropoiesis by the same mechanism as endogenous erythropoietin."}],"pipeline":[{"drug_id":"venetoclax-rituximab","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"talazoparib-with-enzalutamide","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talazoparib with enzalutamide","generic_name":"talazoparib-with-enzalutamide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP enzymes and androgen receptor","drug_class":"PARP inhibitor and androgen receptor inhibitor","quality_score":10,"revenue":"2194","mechanism":""},{"drug_id":"lorlatinib-with-chemotherapy-2","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorlatinib with chemotherapy 2","generic_name":"lorlatinib-with-chemotherapy-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"ALK","drug_class":"ALK inhibitor","quality_score":40,"revenue":"798","mechanism":""},{"drug_id":"naabak-eyedrops","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NAABAK eyedrops","company_name":"Laboratoires Thea","drug_phase":"marketed","molecular_target":"Ocular inflammation and discomfort","drug_class":"Ophthalmic solution","quality_score":8,"revenue":null,"mechanism":""},{"drug_id":"pregabalin-25-mg","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pregabalin 25 MG","company_name":"Ajou University School of Medicine","drug_phase":"marketed","molecular_target":"α2δ subunit of voltage-gated calcium channels","drug_class":"Anticonvulsant","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"pregabalin-25-mg","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pregabalin 25 MG","company_name":"Ajou University School of Medicine","drug_phase":"marketed","molecular_target":"α2δ subunit of voltage-gated calcium channels","drug_class":"Anticonvulsant","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"tumor-tissue","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"mdv3100","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MDV3100","generic_name":"mdv3100","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Prostate-specific antigen","drug_class":"Androgen receptor inhibitor","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"alpha-blocker-monotherapy","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"alpha blocker monotherapy","company_name":"Samsung Medical Center","drug_phase":"marketed","molecular_target":"alpha-1 adrenergic receptors","drug_class":"Alpha blocker","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"alpha-blocker-monotherapy","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"alpha blocker monotherapy","company_name":"Samsung Medical Center","drug_phase":"marketed","molecular_target":"alpha-1 adrenergic receptors","drug_class":"Alpha blocker","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"l-cysteine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-cysteine","company_name":"Louisiana State University Health Sciences Center Shreveport","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Amino acid derivative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"l-cysteine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-cysteine","company_name":"Louisiana State University Health Sciences Center Shreveport","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Amino acid derivative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"l-cysteine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-cysteine","company_name":"Louisiana State University Health Sciences Center Shreveport","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Amino acid derivative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"l-cysteine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-cysteine","company_name":"Louisiana State University Health Sciences Center Shreveport","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Amino acid derivative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"l-cysteine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-cysteine","company_name":"Louisiana State University Health Sciences Center Shreveport","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Amino acid derivative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"l-cysteine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-cysteine","company_name":"Louisiana State University Health Sciences Center Shreveport","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Amino acid derivative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"l-cysteine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-cysteine","company_name":"Louisiana State University Health Sciences Center Shreveport","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Amino acid derivative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"l-cysteine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"L-cysteine","company_name":"Louisiana State University Health Sciences Center Shreveport","drug_phase":"marketed","molecular_target":"Cystine/glutamate transporter","drug_class":"Amino acid derivative","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"detralex","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Detralex","company_name":"Servier Russia","drug_phase":"marketed","molecular_target":"Venous tone and microcirculation","drug_class":"Venoactive drug","quality_score":null,"revenue":null,"mechanism":"Detralex works by enhancing venous tone and microcirculation through the action of diosmin and hesperidin."},{"drug_id":"detralex","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Detralex","company_name":"Servier Russia","drug_phase":"marketed","molecular_target":"Venous tone and microcirculation","drug_class":"Venoactive drug","quality_score":null,"revenue":null,"mechanism":"Detralex works by enhancing venous tone and microcirculation through the action of diosmin and hesperidin."},{"drug_id":"ngenla-somatrogon","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NGENLA (Somatrogon)","generic_name":"ngenla-somatrogon","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"Recombinant human growth hormone","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08052666","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08052666","generic_name":"pf-08052666","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in disease pathways","drug_class":"Small molecule inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-08052666","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08052666","generic_name":"pf-08052666","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in disease pathways","drug_class":"Small molecule inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"stopping-dupilumab","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Stopping dupilumab","company_name":"University Hospital, Toulouse","drug_phase":"marketed","molecular_target":"Interleukin-4 receptor alpha subunit (IL-4Rα)","drug_class":"Monoclonal antibody","quality_score":0,"revenue":null,"mechanism":"Dupilumab is a human monoclonal antibody that binds to the interleukin-4 receptor alpha subunit, blocking the signaling of IL-4 and IL-13, which are key cytokines in type 2 inflammation."},{"drug_id":"stopping-dupilumab","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Stopping dupilumab","company_name":"University Hospital, Toulouse","drug_phase":"marketed","molecular_target":"Interleukin-4 receptor alpha subunit (IL-4Rα)","drug_class":"Monoclonal antibody","quality_score":0,"revenue":null,"mechanism":"Dupilumab is a human monoclonal antibody that binds to the interleukin-4 receptor alpha subunit, blocking the signaling of IL-4 and IL-13, which are key cytokines in type 2 inflammation."},{"drug_id":"stopping-dupilumab","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Stopping dupilumab","company_name":"University Hospital, Toulouse","drug_phase":"marketed","molecular_target":"Interleukin-4 receptor alpha subunit (IL-4Rα)","drug_class":"Monoclonal antibody","quality_score":0,"revenue":null,"mechanism":"Dupilumab is a human monoclonal antibody that binds to the interleukin-4 receptor alpha subunit, blocking the signaling of IL-4 and IL-13, which are key cytokines in type 2 inflammation."},{"drug_id":"isauvuconazole-group","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"coenzyme-q10","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Coenzyme Q10","company_name":"Nanjing Medical University","drug_phase":"marketed","molecular_target":"Mitochondrial electron transport chain","drug_class":"Dietary supplement","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"coenzyme-q10","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Coenzyme Q10","company_name":"Nanjing Medical University","drug_phase":"marketed","molecular_target":"Mitochondrial electron transport chain","drug_class":"Dietary supplement","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"coenzyme-q10","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Coenzyme Q10","company_name":"Nanjing Medical University","drug_phase":"marketed","molecular_target":"Mitochondrial electron transport chain","drug_class":"Dietary supplement","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"rsvpref-120-g","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RSVpreF 120 µg","generic_name":"rsvpref-120-g","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Prefusion form of the RSV F protein","drug_class":"Recombinant subunit vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"cessation-phase-nicotine-patch-nicotine-mini-lozenge","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge","company_name":"University of Wisconsin, Madison","drug_phase":"marketed","molecular_target":"Nicotinic acetylcholine receptors","drug_class":"Nicotine replacement therapy (NRT)","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"89zr-zr-crefmirlimab-berdoxam","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"[89Zr]Zr-crefmirlimab berdoxam","generic_name":"89zr-zr-crefmirlimab-berdoxam","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Fibroblast Activation Protein (FAP)","drug_class":"Radiolabeled Monoclonal Antibody","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"losartan-amlodpine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"losartan/amlodpine","company_name":"University of Pavia","drug_phase":"marketed","molecular_target":"Angiotensin II receptors (AT1) and L-type calcium channels","drug_class":"Angiotensin II receptor blocker (ARB) / Calcium channel blocker (CCB)","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ketamine-perfusion","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ketamine perfusion","company_name":"University Tunis El Manar","drug_phase":"marketed","molecular_target":"NMDA receptor","drug_class":"Dissociative anesthetic","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"ketamine-perfusion","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ketamine perfusion","company_name":"University Tunis El Manar","drug_phase":"marketed","molecular_target":"NMDA receptor","drug_class":"Dissociative anesthetic","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"ifo","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IFO","company_name":"Italian Sarcoma Group","drug_phase":"marketed","molecular_target":"DNA","drug_class":"Alkylating Agent","quality_score":null,"revenue":null,"mechanism":"Ifosfamide is an alkylating agent that cross-links DNA, preventing cell replication and inducing apoptosis."},{"drug_id":"ifo","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IFO","company_name":"Italian Sarcoma Group","drug_phase":"marketed","molecular_target":"DNA","drug_class":"Alkylating Agent","quality_score":null,"revenue":null,"mechanism":"Ifosfamide is an alkylating agent that cross-links DNA, preventing cell replication and inducing apoptosis."},{"drug_id":"ifo","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IFO","company_name":"Italian Sarcoma Group","drug_phase":"marketed","molecular_target":"DNA","drug_class":"Alkylating Agent","quality_score":null,"revenue":null,"mechanism":"Ifosfamide is an alkylating agent that cross-links DNA, preventing cell replication and inducing apoptosis."},{"drug_id":"thyrogen","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Thyrogen","company_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","drug_phase":"marketed","molecular_target":"Thyrotropin receptor","drug_class":"Recombinant human thyrotropin","quality_score":0,"revenue":null,"mechanism":"Thyrogen is a recombinant human thyrotropin that stimulates thyroid cells to produce and release thyroid hormones, aiding in the diagnosis and treatment of thyroid cancer."},{"drug_id":"pf-06939999-in-combination-with-docetaxel","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 in combination with docetaxel","generic_name":"pf-06939999-in-combination-with-docetaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein kinase","drug_class":"Small molecule inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pitavastin-4mg","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pitavastin 4mg","company_name":"University of Kansas Medical Center","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"Statins","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"pitavastin-4mg","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pitavastin 4mg","company_name":"University of Kansas Medical Center","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"Statins","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"ga-68-dotatoc","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ga-68-DOTATOC","company_name":"Weill Medical College of Cornell University","drug_phase":"marketed","molecular_target":"Somatostatin receptors (SSTRs) on neuroendocrine tumor cells","drug_class":"Radiopharmaceutical","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avacincaptad-pegol-sodium","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AVACINCAPTAD PEGOL SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"Complement Inhibitors","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"avacincaptad-pegol-sodium","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AVACINCAPTAD PEGOL SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"Complement Inhibitors","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"insulin-injections","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Insulin injections","company_name":"University of Campania Luigi Vanvitelli","drug_phase":"marketed","molecular_target":"Insulin receptor","drug_class":"Insulin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"twinrix-for-atn-025","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Twinrix for ATN 025","company_name":"University of North Carolina, Chapel Hill","drug_phase":"marketed","molecular_target":"Hepatitis A virus and Hepatitis B virus","drug_class":"Vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"anti-vegf-drug","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Anti-VEGF drug","company_name":"Xiaodong Sun","drug_phase":"marketed","molecular_target":"VEGF-A","drug_class":"Anti-VEGF","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"anti-vegf-drug","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Anti-VEGF drug","company_name":"Xiaodong Sun","drug_phase":"marketed","molecular_target":"VEGF-A","drug_class":"Anti-VEGF","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dupilumab-therapy","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dupilumab therapy","company_name":"National Medical Research Center for Children's Health, Russian Federation","drug_phase":"marketed","molecular_target":"IL-4Rα","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dupilumab-therapy","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dupilumab therapy","company_name":"National Medical Research Center for Children's Health, Russian Federation","drug_phase":"marketed","molecular_target":"IL-4Rα","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dupilumab-therapy","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dupilumab therapy","company_name":"National Medical Research Center for Children's Health, Russian Federation","drug_phase":"marketed","molecular_target":"IL-4Rα","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"veklury","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Veklury","company_name":"ANRS, Emerging Infectious Diseases","drug_phase":"marketed","molecular_target":"NS5, Replicase polyprotein 1ab","drug_class":"Nucleoside analog prodrug","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"raltegravir-use-ral-as-a-simplification-strategy","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Raltegravir (Use RAL as a simplification strategy)","company_name":"Hospital Carlos III, Madrid","drug_phase":"marketed","molecular_target":"C-C chemokine receptor type 1, Gag-Pol polyprotein, Integrase","drug_class":"Integrase inhibitors","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"amnio-maxx-dual-layer-amnion-patch","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amnio-Maxx® Dual Layer Amnion Patch","company_name":"Royal Biologics","drug_phase":"marketed","molecular_target":"Wound healing and tissue regeneration","drug_class":"Biologic tissue graft","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"amnio-maxx-dual-layer-amnion-patch","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amnio-Maxx® Dual Layer Amnion Patch","company_name":"Royal Biologics","drug_phase":"marketed","molecular_target":"Wound healing and tissue regeneration","drug_class":"Biologic tissue graft","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"blinded-clopidogrel","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Blinded clopidogrel","company_name":"VA Office of Research and Development","drug_phase":"marketed","molecular_target":"P2Y12 receptor","drug_class":"Antiplatelet agents","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"recombinant-b-type-natriuretic-peptide","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"recombinant B-type, natriuretic peptide","company_name":"University of Texas Southwestern Medical Center","drug_phase":"marketed","molecular_target":"Natriuretic peptide receptor-A (NPR-A)","drug_class":"Natriuretic peptides","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"recombinant-b-type-natriuretic-peptide","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"recombinant B-type, natriuretic peptide","company_name":"University of Texas Southwestern Medical Center","drug_phase":"marketed","molecular_target":"Natriuretic peptide receptor-A (NPR-A)","drug_class":"Natriuretic peptides","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"different-antibiotic-combinations","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Different Antibiotic Combinations","company_name":"Inonu University","drug_phase":"marketed","molecular_target":"Multiple bacterial targets including cell wall synthesis, protein synthesis, and DNA replication","drug_class":"Antibiotic combinations","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"different-antibiotic-combinations","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Different Antibiotic Combinations","company_name":"Inonu University","drug_phase":"marketed","molecular_target":"Multiple bacterial targets including cell wall synthesis, protein synthesis, and DNA replication","drug_class":"Antibiotic combinations","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"different-antibiotic-combinations","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Different Antibiotic Combinations","company_name":"Inonu University","drug_phase":"marketed","molecular_target":"Multiple bacterial targets including cell wall synthesis, protein synthesis, and DNA replication","drug_class":"Antibiotic combinations","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-07853578","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07853578","generic_name":"pf-07853578","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"[specific protein]","drug_class":"Small molecule inhibitor","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"pf-07853578","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07853578","generic_name":"pf-07853578","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"[specific protein]","drug_class":"Small molecule inhibitor","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"fentanyl-f2","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fentanyl (F2)","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"fentanyl-f2","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fentanyl (F2)","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor","drug_class":"Synthetic opioid","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"intravenous-ketamine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Intravenous Ketamine","company_name":"Rebecca Price","drug_phase":"marketed","molecular_target":"NMDA receptors","drug_class":"Dissociative anesthetic","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"intravenous-ketamine","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Intravenous Ketamine","company_name":"Rebecca Price","drug_phase":"marketed","molecular_target":"NMDA receptors","drug_class":"Dissociative anesthetic","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"oral-viscous-budesonide-ovb","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Oral Viscous Budesonide (OVB)","company_name":"Azienda Policlinico Umberto I","drug_phase":"marketed","molecular_target":"Glucocorticoid receptors","drug_class":"Corticosteroids","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin-hydrochloride","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Liposomal doxorubicin hydrochloride","company_name":"Cephalon, Inc.","drug_phase":"marketed","molecular_target":"DNA and topoisomerase II","drug_class":"Antineoplastic agent","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin-hydrochloride","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Liposomal doxorubicin hydrochloride","company_name":"Cephalon, Inc.","drug_phase":"marketed","molecular_target":"DNA and topoisomerase II","drug_class":"Antineoplastic agent","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"rfviia-rfviia-txa","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"rFVIIa, rFVIIa + TXA","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"Extrinsic coagulation pathway and fibrinolysis inhibition","drug_class":"Hemostatic agents","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"rfviia-rfviia-txa","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"rFVIIa, rFVIIa + TXA","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"Extrinsic coagulation pathway and fibrinolysis inhibition","drug_class":"Hemostatic agents","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"rfviia-rfviia-txa","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"rFVIIa, rFVIIa + TXA","company_name":"Oslo University Hospital","drug_phase":"marketed","molecular_target":"Extrinsic coagulation pathway and fibrinolysis inhibition","drug_class":"Hemostatic agents","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"chorionic-gonadotropin-alpha","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Chorionic Gonadotropin, Alpha","company_name":"Copenhagen University Hospital at Herlev","drug_phase":"marketed","molecular_target":"LH/CG receptor","drug_class":"Gonadotropins","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"chorionic-gonadotropin-alpha","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Chorionic Gonadotropin, Alpha","company_name":"Copenhagen University Hospital at Herlev","drug_phase":"marketed","molecular_target":"LH/CG receptor","drug_class":"Gonadotropins","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"intracanalicular-dexamethasone-0-4-mg-insert","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Intracanalicular Dexamethasone, 0.4 mg insert","company_name":"Wolstan and Goldberg Eye Associates","drug_phase":"marketed","molecular_target":"Inflammatory mediators and immune cells in the ocular tissues","drug_class":"Corticosteroids","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"intracanalicular-dexamethasone-0-4-mg-insert","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Intracanalicular Dexamethasone, 0.4 mg insert","company_name":"Wolstan and Goldberg Eye Associates","drug_phase":"marketed","molecular_target":"Inflammatory mediators and immune cells in the ocular tissues","drug_class":"Corticosteroids","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"semaglutide-or-tirzepatide","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"semaglutide or tirzepatide","company_name":"Mayo Clinic","drug_phase":"marketed","molecular_target":"GLP-1 receptor","drug_class":"GLP-1 receptor agonist","quality_score":52,"revenue":null,"mechanism":"Semaglutide and tirzepatide are GLP-1 receptor agonists that enhance glucose-dependent insulin secretion and reduce glucagon secretion, leading to improved glycemic control and weight loss."},{"drug_id":"test-formulation-treatment-a","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"elrantamab","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elrantamab","generic_name":"elrantamab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCMA (B-cell maturation antigen)","drug_class":"Bispecific Antibody","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07220060","generic_name":"pf-07220060","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in disease pathways","drug_class":"Small molecule inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07220060","generic_name":"pf-07220060","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in disease pathways","drug_class":"Small molecule inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"tegoprazan-50-mg","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tegoprazan 50 mg","company_name":"First People's Hospital of Hangzhou","drug_phase":"marketed","molecular_target":"H+/K+-ATPase","drug_class":"Potassium-Competitive Acid Blocker (P-CAB)","quality_score":42,"revenue":null,"mechanism":"Tegoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits the H+/K+-ATPase enzyme, reducing gastric acid secretion."},{"drug_id":"tegoprazan-50-mg","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tegoprazan 50 mg","company_name":"First People's Hospital of Hangzhou","drug_phase":"marketed","molecular_target":"H+/K+-ATPase","drug_class":"Potassium-Competitive Acid Blocker (P-CAB)","quality_score":42,"revenue":null,"mechanism":"Tegoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits the H+/K+-ATPase enzyme, reducing gastric acid secretion."},{"drug_id":"pf-07248144","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07248144","generic_name":"pf-07248144","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in disease pathways","drug_class":"Small molecule inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"pf-07248144","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07248144","generic_name":"pf-07248144","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in disease pathways","drug_class":"Small molecule inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"omega-3-acid-4-grams-per-day","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omega-3 acid 4 grams per day","company_name":"Inje University","drug_phase":"marketed","molecular_target":"Triglyceride synthesis, platelet aggregation, inflammatory pathways","drug_class":"Dietary supplement","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"omega-3-acid-4-grams-per-day","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omega-3 acid 4 grams per day","company_name":"Inje University","drug_phase":"marketed","molecular_target":"Triglyceride synthesis, platelet aggregation, inflammatory pathways","drug_class":"Dietary supplement","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"pf-08046045","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08046045","generic_name":"pf-08046045","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in cancer cell proliferation","drug_class":"Small molecule inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"pf-08046045","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-08046045","generic_name":"pf-08046045","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in cancer cell proliferation","drug_class":"Small molecule inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"oral-mini-pulse","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"oral mini pulse","company_name":"Cairo University","drug_phase":"marketed","molecular_target":"Glucocorticoid receptors","drug_class":"Corticosteroids","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"oral-mini-pulse","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"oral mini pulse","company_name":"Cairo University","drug_phase":"marketed","molecular_target":"Glucocorticoid receptors","drug_class":"Corticosteroids","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"donepezil-aricept","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Donepezil (Aricept)","company_name":"University of Virginia","drug_phase":"marketed","molecular_target":"Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon","drug_class":"Acetylcholinesterase Inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"donepezil-aricept","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Donepezil (Aricept)","company_name":"University of Virginia","drug_phase":"marketed","molecular_target":"Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon","drug_class":"Acetylcholinesterase Inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"pf-07293893","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07293893","generic_name":"pf-07293893","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) pathway","drug_class":"JAK inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"pf-07293893","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07293893","generic_name":"pf-07293893","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) pathway","drug_class":"JAK inhibitor","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"pf-06954522","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06954522","generic_name":"pf-06954522","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"[specific target]","drug_class":"Small molecule inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06954522","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06954522","generic_name":"pf-06954522","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"[specific target]","drug_class":"Small molecule inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06954522","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06954522","generic_name":"pf-06954522","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"[specific target]","drug_class":"Small molecule inhibitor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-07921585","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07921585","generic_name":"pf-07921585","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein involved in cancer cell proliferation","drug_class":"Small molecule inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"cmp-001","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CMP 001","generic_name":"cmp-001","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"TLR9","drug_class":"Immunomodulatory Agent","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"cmp-001","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CMP 001","generic_name":"cmp-001","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"TLR9","drug_class":"Immunomodulatory Agent","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"cmp-001","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CMP 001","generic_name":"cmp-001","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"TLR9","drug_class":"Immunomodulatory Agent","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"gatifloxacin-0-3","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gatifloxacin 0.3%","company_name":"Innovative Medical","drug_phase":"marketed","molecular_target":"DNA gyrase and topoisomerase IV","drug_class":"Fluoroquinolone","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"quetiapine-600mg","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapine 600mg","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"[\"serotonin 5-HT2A receptors\", \"dopamine D2 receptors\"]","drug_class":"atypical antipsychotic","quality_score":55,"revenue":null,"mechanism":"Quetiapine is an atypical antipsychotic that acts as a serotonin and dopamine receptor antagonist."},{"drug_id":"loteprednol-and-tobramycin","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Loteprednol and tobramycin","company_name":"Bausch & Lomb Incorporated","drug_phase":"marketed","molecular_target":"Inflammatory mediators and bacterial protein synthesis","drug_class":"Corticosteroid/aminoglycoside combination","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"other-treatment","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Other treatment","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"other-treatment","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Other treatment","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tdf-treatment","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TDF treatment","company_name":"New Discovery LLC","drug_phase":"marketed","molecular_target":"Viral reverse transcriptase","drug_class":"Nucleotide reverse transcriptase inhibitor (NtRTI)","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tdf-treatment","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TDF treatment","company_name":"New Discovery LLC","drug_phase":"marketed","molecular_target":"Viral reverse transcriptase","drug_class":"Nucleotide reverse transcriptase inhibitor (NtRTI)","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"intranasal-glugagon","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Intranasal glugagon","company_name":"A.O.U. Città della Salute e della Scienza","drug_phase":"marketed","molecular_target":"Liver","drug_class":"Hormonal","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"imotun","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imotun","company_name":"Chong Kun Dang Pharmaceutical","drug_phase":"marketed","molecular_target":"Specific signaling molecules","drug_class":"Biological modulator","quality_score":8,"revenue":null,"mechanism":""},{"drug_id":"linoladiol-estradiol","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Linoladiol Estradiol","company_name":"Medical University of Vienna","drug_phase":"marketed","molecular_target":"Estrogen receptors (ERα and ERβ)","drug_class":"Synthetic estrogen","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"linoladiol-estradiol","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Linoladiol Estradiol","company_name":"Medical University of Vienna","drug_phase":"marketed","molecular_target":"Estrogen receptors (ERα and ERβ)","drug_class":"Synthetic estrogen","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"fluticasone-furoate-umeclidinium-vilanterol-fuv","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)","company_name":"Thammasat University","drug_phase":"marketed","molecular_target":"Airway inflammation and bronchoconstriction","drug_class":"Combination inhaler (ICS/LAMA/LABA)","quality_score":30,"revenue":null,"mechanism":"FUV is a triple-combination inhaler that integrates a corticosteroid (fluticasone furoate), a long-acting muscarinic antagonist (umeclidinium), and a long-acting beta2-adrenergic agonist (vilanterol) to provide synergistic bronchodilation and anti-inflammatory effects."},{"drug_id":"peri-articular-infiltration","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"peri-articular infiltration","company_name":"University of Warwick","drug_phase":"marketed","molecular_target":"Synovial membrane and surrounding soft tissues","drug_class":"Corticosteroids and local anesthetics","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"peri-articular-infiltration","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"peri-articular infiltration","company_name":"University of Warwick","drug_phase":"marketed","molecular_target":"Synovial membrane and surrounding soft tissues","drug_class":"Corticosteroids and local anesthetics","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"peri-articular-infiltration","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"peri-articular infiltration","company_name":"University of Warwick","drug_phase":"marketed","molecular_target":"Synovial membrane and surrounding soft tissues","drug_class":"Corticosteroids and local anesthetics","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"0-09-bromfenac","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"0,09% Bromfenac","company_name":"Hospital de La Luz","drug_phase":"marketed","molecular_target":"Cyclooxygenase-2 (COX-2)","drug_class":"Nonsteroidal Anti-Inflammatory Drug (NSAID)","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"treatment-choice","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Treatment Choice","company_name":"Astex Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"DNA repair enzyme","drug_class":"Small molecule inhibitor","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"treatment-choice","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Treatment Choice","company_name":"Astex Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"DNA repair enzyme","drug_class":"Small molecule inhibitor","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"treatment-choice","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Treatment Choice","company_name":"Astex Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"DNA repair enzyme","drug_class":"Small molecule inhibitor","quality_score":14,"revenue":null,"mechanism":""},{"drug_id":"ephedrine-continuous-infusion","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ephedrine, continuous infusion","company_name":"University of Parma","drug_phase":"marketed","molecular_target":"Alpha and beta-adrenergic receptors","drug_class":"Sympathomimetic amine","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"ephedrine-continuous-infusion","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ephedrine, continuous infusion","company_name":"University of Parma","drug_phase":"marketed","molecular_target":"Alpha and beta-adrenergic receptors","drug_class":"Sympathomimetic amine","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"ketamine-0-5mg-kg","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ketamine 0.5mg/kg","company_name":"The University of Hong Kong","drug_phase":"marketed","molecular_target":"NMDA receptors","drug_class":"Dissociative anesthetic","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"ketamine-0-5mg-kg","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ketamine 0.5mg/kg","company_name":"The University of Hong Kong","drug_phase":"marketed","molecular_target":"NMDA receptors","drug_class":"Dissociative anesthetic","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"naabak-eyedrops","indication_name":"Unknown indication","indication_type":"pipeline","phase":"","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NAABAK eyedrops","company_name":"Laboratoires Thea","drug_phase":"marketed","molecular_target":"Ocular inflammation and discomfort","drug_class":"Ophthalmic solution","quality_score":8,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":87,"totalPipeline":137},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}